A 24-year-old presents with three days of extreme thirst, frequent urination, rapid deep breathing, blood glucose of 480 mg/dL, elevated plasma ketones, and blood pH of 7.1. The pathophysiology most consistent with this presentation is:
ADecades of progressive insulin resistance with compensatory hyperinsulinemia now failing
BAutoimmune destruction of beta cells leaving no endogenous insulin, allowing unopposed glucagon to drive continuous hepatic glucose output and ketogenesis
CExtreme hyperglycemia causing osmotic fluid shifts without ketone accumulation or acidosis
DHyperosmolar hyperglycemic state from end-stage Type 2 diabetes
This is classic diabetic ketoacidosis (DKA) from Type 1 diabetes. Absolute insulin absence allows glucagon to act without opposition: hepatic glycogenolysis and gluconeogenesis drive glucose sky-high, and fatty acid mobilization floods the liver with substrate for ketone body synthesis. Ketones accumulate faster than peripheral tissues can consume them, producing the anion-gap metabolic acidosis reflected by pH 7.1 and the compensatory Kussmaul breathing. DKA is the hallmark presentation of Type 1. Options C and D describe hyperosmolar hyperglycemic state, which has extreme glucose but minimal or no ketoacidosis because residual insulin in Type 2 suppresses ketogenesis.
Question 2 Multiple Choice
A patient with well-controlled Type 2 diabetes feels healthy and has no current symptoms. Their physician advises that tight glycemic control is no longer necessary. This advice is flawed because:
AFeeling healthy reliably indicates that complications are not developing — so the advice is clinically sound
BComplications arise exclusively from insulin resistance, which persists regardless of blood glucose levels
CChronic hyperglycemia itself drives microvascular and macrovascular damage through glycation and oxidative stress — HbA1c reflects cumulative exposure that is accruing silently even without symptoms
DType 2 diabetes only requires tight control when the patient is symptomatic or ketosis is present
Diabetic complications develop insidiously from cumulative glycemic exposure, not from acute symptomatic episodes. Glucose reacts non-enzymatically with proteins (glycation), forms advanced glycation end-products (AGEs), and generates reactive oxygen species that progressively damage small and large vessels. Retinopathy, nephropathy, and neuropathy may be advanced before symptoms appear. HbA1c quantifies average glucose over 2–3 months; the damage this reflects has already been done. 'Feeling healthy' is precisely the problem — the disease progresses silently while subjective well-being remains intact.
Question 3 True / False
Diabetic ketoacidosis (DKA) is equally common in Type 1 and Type 2 diabetes because both conditions feature hyperglycemia, which is the proximate driver of ketogenesis.
TTrue
FFalse
Answer: False
DKA requires near-complete insulin absence, which allows glucagon to drive unrestricted fatty acid mobilization and hepatic ketogenesis. In Type 1, beta cells are destroyed — insulin is truly absent. In Type 2, even significantly impaired beta cells typically retain enough secretory capacity to produce low-level basal insulin, which is sufficient to suppress the extreme ketogenesis that causes DKA. In Type 2, the crisis is instead hyperosmolar hyperglycemic state — severe glucose elevation causing osmotic fluid shifts and dehydration without significant ketoacidosis. Hyperglycemia is shared; DKA is not.
Question 4 True / False
HbA1c is clinically useful for monitoring diabetes management because glycated hemoglobin accumulates in proportion to average blood glucose concentration over the preceding 2–3 months, providing a time-integrated marker of glycemic exposure.
TTrue
FFalse
Answer: True
Hemoglobin undergoes irreversible non-enzymatic glycation at a rate proportional to ambient glucose concentration. Since red blood cells survive roughly 90–120 days, HbA1c reflects the average glucose over that lifespan. A single fasting glucose reading captures a snapshot; HbA1c captures the cumulative burden. This makes it ideal for assessing long-term glycemic control and predicting the risk of microvascular complications, which correlate with time-averaged glucose exposure rather than any single measurement.
Question 5 Short Answer
Explain why Type 1 and Type 2 diabetes both cause hyperglycemia but through fundamentally different pathophysiological mechanisms.
Think about your answer, then reveal below.
Model answer: Both conditions disrupt glucose homeostasis, but at different points in the regulatory loop. In Type 1, autoimmune destruction eliminates beta cells entirely — there is no insulin output. Without insulin, GLUT4 does not translocate to muscle and fat cell membranes, glycogen synthesis halts, and glucagon is completely unopposed, driving continuous hepatic glucose production. Cells behave as if starving despite glucose excess. In Type 2, the problem begins upstream with insulin resistance in target tissues. Beta cells initially compensate by secreting more insulin, maintaining near-normal glucose for years. Only when beta cells exhaust under sustained secretory demand does frank hyperglycemia appear. The distinction matters clinically: Type 1 always requires exogenous insulin because no endogenous source remains; Type 2 can often be managed with insulin sensitizers or incretin-based drugs because residual beta cell function and tissue insulin signaling can be potentiated.
A common misconception is that Type 1 and Type 2 differ only in severity. They differ in mechanism: absence of insulin production versus resistance to insulin action. This determines the risk of DKA (only Type 1 in typical cases), the natural history (acute onset vs. insidious progression), and the therapeutic approach.